JP2011528371A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011528371A5 JP2011528371A5 JP2011518897A JP2011518897A JP2011528371A5 JP 2011528371 A5 JP2011528371 A5 JP 2011528371A5 JP 2011518897 A JP2011518897 A JP 2011518897A JP 2011518897 A JP2011518897 A JP 2011518897A JP 2011528371 A5 JP2011528371 A5 JP 2011528371A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- item
- immunogenic
- particle
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002163 immunogen Effects 0.000 claims description 26
- 239000002245 particle Substances 0.000 claims description 26
- 241000894007 species Species 0.000 claims description 16
- 150000003904 phospholipids Chemical class 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- 239000000427 antigen Substances 0.000 claims description 10
- 102000036639 antigens Human genes 0.000 claims description 10
- 108091007433 antigens Proteins 0.000 claims description 10
- 150000001413 amino acids Chemical class 0.000 claims description 9
- 150000002632 lipids Chemical class 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 101800002011 Amphipathic peptide Proteins 0.000 claims description 6
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims description 4
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims description 4
- 101710154606 Hemagglutinin Proteins 0.000 claims description 4
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 4
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 4
- 101710176177 Protein A56 Proteins 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 230000001580 bacterial effect Effects 0.000 claims description 4
- -1 cationic lipid Chemical class 0.000 claims description 4
- 239000000185 hemagglutinin Substances 0.000 claims description 4
- 230000008685 targeting Effects 0.000 claims description 4
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 3
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 2
- 108010028921 Lipopeptides Proteins 0.000 claims description 2
- 102000004895 Lipoproteins Human genes 0.000 claims description 2
- 108090001030 Lipoproteins Proteins 0.000 claims description 2
- 108091034117 Oligonucleotide Proteins 0.000 claims description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 2
- BJVCSICIEDHBNI-UHFFFAOYSA-N benzo[b][1,8]naphthyridine Chemical class N1=CC=CC2=CC3=CC=CC=C3N=C21 BJVCSICIEDHBNI-UHFFFAOYSA-N 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- SQQXRXKYTKFFSM-UHFFFAOYSA-N chembl1992147 Chemical compound OC1=C(OC)C(OC)=CC=C1C1=C(C)C(C(O)=O)=NC(C=2N=C3C4=NC(C)(C)N=C4C(OC)=C(O)C3=CC=2)=C1N SQQXRXKYTKFFSM-UHFFFAOYSA-N 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 229940125810 compound 20 Drugs 0.000 claims description 2
- 239000002577 cryoprotective agent Substances 0.000 claims description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000002158 endotoxin Substances 0.000 claims description 2
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 claims description 2
- 229940124669 imidazoquinoline Drugs 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims description 2
- 230000003308 immunostimulating effect Effects 0.000 claims description 2
- 206010022000 influenza Diseases 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 229920006008 lipopolysaccharide Polymers 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 230000004048 modification Effects 0.000 claims description 2
- 238000012986 modification Methods 0.000 claims description 2
- 239000003002 pH adjusting agent Substances 0.000 claims description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 2
- 239000002516 radical scavenger Substances 0.000 claims description 2
- 229930182490 saponin Natural products 0.000 claims description 2
- 150000007949 saponins Chemical class 0.000 claims description 2
- 229940031439 squalene Drugs 0.000 claims description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- 230000002194 synthesizing effect Effects 0.000 claims description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000004873 anchoring Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8094208P | 2008-07-15 | 2008-07-15 | |
| US61/080,942 | 2008-07-15 | ||
| PCT/US2009/050764 WO2010009277A2 (en) | 2008-07-15 | 2009-07-15 | Immunogenic amphipathic peptide compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011528371A JP2011528371A (ja) | 2011-11-17 |
| JP2011528371A5 true JP2011528371A5 (enExample) | 2012-08-30 |
| JP5781929B2 JP5781929B2 (ja) | 2015-09-24 |
Family
ID=41478598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011518897A Expired - Fee Related JP5781929B2 (ja) | 2008-07-15 | 2009-07-15 | 免疫原性の両親媒性ペプチド組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20110250237A1 (enExample) |
| EP (1) | EP2313085A2 (enExample) |
| JP (1) | JP5781929B2 (enExample) |
| CA (1) | CA2730737A1 (enExample) |
| WO (1) | WO2010009277A2 (enExample) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7082569B2 (en) | 2001-01-17 | 2006-07-25 | Outlooksoft Corporation | Systems and methods providing dynamic spreadsheet functionality |
| US20100015171A1 (en) * | 2008-07-15 | 2010-01-21 | Statens Serum Institute | Vaccines comprising tb 10.4 |
| CN102762226A (zh) * | 2009-06-10 | 2012-10-31 | 诺华有限公司 | 含苯并萘啶的疫苗 |
| SI3178490T1 (sl) * | 2009-07-15 | 2022-08-31 | Glaxosmithkline Biologicals S.A. | Sestavki proteina F RSV-ja in postopki za pripravo le-teh |
| WO2011130379A1 (en) * | 2010-04-13 | 2011-10-20 | Novartis Ag | Benzonapthyridine compositions and uses thereof |
| ES2649896T3 (es) | 2010-07-06 | 2018-01-16 | Glaxosmithkline Biologicals Sa | Emulsiones catiónicas de aceite en agua |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP3431485B2 (en) | 2010-10-01 | 2024-09-04 | ModernaTX, Inc. | Engineered nucleic acids and methods of use thereof |
| WO2012065263A1 (en) * | 2010-11-15 | 2012-05-24 | Sanofi Pasteur Limited | Immunogenic compositions |
| WO2012089231A1 (en) * | 2010-12-30 | 2012-07-05 | Okairòs Ag | Paramyxovirus vaccines |
| US10357568B2 (en) | 2011-03-24 | 2019-07-23 | Glaxosmithkline Biologicals S.A. | Adjuvant nanoemulsions with phospholipids |
| WO2012135805A2 (en) | 2011-03-31 | 2012-10-04 | modeRNA Therapeutics | Delivery and formulation of engineered nucleic acids |
| SI3275892T1 (sl) | 2011-05-13 | 2020-06-30 | Glaxosmithkline Biologicals S.A. | Prefuzijski RSV F antigeni |
| US20140206753A1 (en) | 2011-06-08 | 2014-07-24 | Shire Human Genetic Therapies, Inc. | Lipid nanoparticle compositions and methods for mrna delivery |
| US9655845B2 (en) | 2011-07-06 | 2017-05-23 | Glaxosmithkline Biologicals, S.A. | Oil-in-water emulsions that contain nucleic acids |
| MX350258B (es) | 2011-07-06 | 2017-08-31 | Novartis Ag | Emulsiones cationicas de aceite en agua. |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2763701B1 (en) | 2011-10-03 | 2018-12-19 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| KR20140102759A (ko) | 2011-12-16 | 2014-08-22 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물 |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
| DE18200782T1 (de) | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| AU2013295242C1 (en) | 2012-07-27 | 2018-08-09 | Institut National De La Sante Et De La Recherche Medicale | CD147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia |
| EP2885419A4 (en) | 2012-08-14 | 2016-05-25 | Moderna Therapeutics Inc | ENZYMES AND POLYMERASES FOR RNA SYNTHESIS |
| JP6290212B2 (ja) | 2012-08-16 | 2018-03-07 | アイピエリアン，インコーポレイティド | タウオパチーの処置方法 |
| BR112015011389A2 (pt) | 2012-11-20 | 2017-08-22 | Glaxosmithkline Biologicals Sa | Complexo f do vírus sincicial respiratório, métodos para produzir um complexo f do vírus sincicial respiratório e para indução de uma resposta imunológica a um f de rsv em um indivíduo, e, composição imunogênica |
| US20140141037A1 (en) * | 2012-11-20 | 2014-05-22 | Novartis Ag | Rsv f prefusion trimers |
| CA2892529C (en) | 2012-11-26 | 2023-04-25 | Moderna Therapeutics, Inc. | Terminally modified rna |
| US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
| US20160024181A1 (en) | 2013-03-13 | 2016-01-28 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
| WO2014152211A1 (en) | 2013-03-14 | 2014-09-25 | Moderna Therapeutics, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| AU2014228765A1 (en) * | 2013-03-15 | 2015-10-15 | Medimmune, Llc | Palivizumab epitope-based virus-like particles |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EA201690675A1 (ru) | 2013-10-03 | 2016-08-31 | Модерна Терапьютикс, Инк. | Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности |
| NZ630610A (en) | 2014-02-14 | 2019-05-31 | Ipierian Inc | Tau peptides, anti-tau antibodies, and methods of use thereof |
| DK4023249T3 (da) | 2014-04-23 | 2025-01-13 | Modernatx Inc | Nukleinsyrevacciner |
| EP2974739A1 (en) | 2014-07-15 | 2016-01-20 | Novartis AG | RSVF trimerization domains |
| CN106659777A (zh) | 2014-06-13 | 2017-05-10 | 葛兰素史密丝克莱恩生物有限公司 | 免疫原性组合产品 |
| WO2016011226A1 (en) | 2014-07-16 | 2016-01-21 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| SG11201702627UA (en) * | 2014-10-03 | 2017-04-27 | Engeneic Molecular Delivery Pty Ltd | Enhanced loading of intact, bacterially derived vesicles with small molecule compounds |
| EP3031822A1 (en) * | 2014-12-08 | 2016-06-15 | Novartis AG | Cytomegalovirus antigens |
| CN107106668A (zh) * | 2014-12-10 | 2017-08-29 | 华西亚生医有限公司 | 用于免疫中的有效抗体生产的新颖蛋白质结构 |
| EP3273944B1 (en) * | 2015-03-25 | 2024-11-20 | The Regents of The University of Michigan | Compositions and methods for delivery of biomacromolecule agents |
| CA3001003A1 (en) | 2015-10-05 | 2017-04-13 | Modernatx, Inc. | Methods for therapeutic administration of messenger ribonucleic acid drugs |
| EP3471778A4 (en) | 2016-06-20 | 2020-02-19 | The Regents of The University of Michigan | COMPOSITIONS AND METHODS FOR ADMINISTERING BIOMACROMOLECULAR AGENTS |
| JP7467458B2 (ja) * | 2018-07-30 | 2024-04-15 | 中央研究院 | コアセルベート複合化による治療用ナノ粒子および細菌を処理するためのそれらの使用 |
| KR102184153B1 (ko) * | 2019-02-25 | 2020-11-30 | 부산대학교 산학협력단 | 고분자 지지체 기반의 인플루엔자 바이러스 유사 구조체 및 이의 제조방법 |
| CA3130712A1 (en) * | 2019-03-22 | 2020-10-01 | Kansas State University Research Foundation | Lipid encasing amphipathic peptides |
| JP7704740B2 (ja) | 2019-09-16 | 2025-07-08 | アムジエン・インコーポレーテツド | 薬物送達デバイスの外部滅菌の方法 |
| EP4237085A1 (en) * | 2020-10-28 | 2023-09-06 | Sanofi Pasteur | Liposomes containing tlr4 agonist, preparation and uses thereof |
| WO2022103927A1 (en) * | 2020-11-12 | 2022-05-19 | Shape Biopharmaceuticals Inc. | Immunogenic compositions for coronaviruses |
| EP4384199A4 (en) * | 2021-08-11 | 2025-07-02 | The Regents Of Univ Of California | PEPTIDES FOR MEMBRANES RETAINING A BARRIER FUNCTION |
| WO2025242657A1 (en) | 2024-05-21 | 2025-11-27 | Shape Biopharmaceuticals Ag | Lipopeptide building blocks and aggregates |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0749376B2 (ja) * | 1988-12-16 | 1995-05-31 | アルバニー メディカル カレジ | 免疫原性組成物および医薬組成物 |
| CA2252055C (en) * | 1996-04-11 | 2007-01-16 | The University Of British Columbia | Fusogenic liposomes |
| US7208314B2 (en) * | 2002-02-26 | 2007-04-24 | Mirus Bio Corporation | Compositions and methods for drug delivery using pH sensitive molecules |
| TW201424770A (zh) * | 2003-02-14 | 2014-07-01 | Childrens Hosp & Res Ct Oak | 親脂藥物傳送媒介物及其使用方法 |
| JP4786538B2 (ja) * | 2003-10-01 | 2011-10-05 | チルドレンズ ホスピタル アンド リサーチ センター アット オークランド | 親油性薬物送達ビヒクルおよびその使用方法 |
| WO2007145659A1 (en) * | 2005-11-10 | 2007-12-21 | The Regents Of The University Of California | Synthetic ldl as targeted drug delivery vehicle |
-
2009
- 2009-07-15 WO PCT/US2009/050764 patent/WO2010009277A2/en not_active Ceased
- 2009-07-15 CA CA2730737A patent/CA2730737A1/en not_active Abandoned
- 2009-07-15 EP EP09790499A patent/EP2313085A2/en not_active Withdrawn
- 2009-07-15 JP JP2011518897A patent/JP5781929B2/ja not_active Expired - Fee Related
- 2009-07-15 US US13/003,557 patent/US20110250237A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011528371A5 (enExample) | ||
| Calzas et al. | Innovative mucosal vaccine formulations against influenza A virus infections | |
| DK2729127T3 (en) | METHODS FOR LIPOSOMES PREPARATION | |
| JP4294584B2 (ja) | 核酸ワクチン接種の免疫応答を高めるための方法 | |
| US20170307612A1 (en) | Kit for detecting virus | |
| JP2016504312A5 (enExample) | ||
| Atmar et al. | Adjuvants for pandemic influenza vaccines | |
| JP6119030B2 (ja) | インフルエンザを治療するための組成物及び方法 | |
| CN103118700A (zh) | 合成纳米载体联合疫苗 | |
| JP4634997B2 (ja) | ウィロソーム様粒子 | |
| Carmona-Ribeiro et al. | Cationic nanostructures for vaccines design | |
| JP2013526617A5 (enExample) | ||
| JP7409594B2 (ja) | 医薬組成物、規定のサイズの脂質ベシクル粒子を使用する調製物のための方法、及びそれらの使用 | |
| MX2011002267A (es) | Vacuna. | |
| Desai et al. | Nanoadjuvants: promising bioinspired and biomimetic approaches in vaccine innovation | |
| JP7103726B2 (ja) | 医薬組成物、脂質ベシクル粒子の分粒を含む調製のための方法、及びそれらの使用 | |
| CN103002908B (zh) | 粘膜疫苗 | |
| Chaari et al. | Surface behavior of α-Synuclein and its interaction with phospholipids using the Langmuir monolayer technique: a comparison between monomeric and fibrillar α-Synuclein | |
| Jalilian et al. | Properties and prospects of adjuvants in influenza vaccination-messy precipitates or blessed opportunities? | |
| JPH08506592A (ja) | ３−ｏ−脱アシル化モノホスホリル脂質Ａ含有のインフルエンザワクチン組成物 | |
| US10426828B2 (en) | Compositions of multimeric-multiepitope influenza polypeptides and their production | |
| US20240366747A1 (en) | Universal vaccine for influenza virus based on tetrameric m2 protein incorporated into nanodiscs | |
| TW201217000A (en) | Vaccine compositions based on sticholysin encapsulated into liposomes | |
| CN103282049B (zh) | 免疫原性组合物 | |
| US12006350B2 (en) | Triblock peptide amphiphiles, micelles and methods of use |